Pediatric labeling milestone
Executive Summary
FDA's approval of new labeling for Novartis' seizure therapy Trileptal addressing its use in children and teenagers marks the 100th product to add pediatric information to its label since the implementation of the FDA Modernization Act in 1997, the agency announces Dec. 19. "This is a highly gratifying achievement for our most precious patients, their parents, and their physicians," Acting FDA Commissioner Andrew von Eschenbach said. Since FDAMA was enacted, manufacturers have conducted more than 250 pediatric studies for 125 products compared to only 11 such studies in the seven years prior to the legislation. FDAMA, along with the 2002 Best Pharmaceuticals for Children Act, provide sponsors incentives for conducting pediatric trials (1"The Pink Sheet" May 14, 2001, p. 21)...
You may also be interested in...
Pediatric Labeling Negotiations Limited To 6 Months In Reauthorization Bill
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.